Finanzen von Grifols SA (GRFS)GRFSGrifols SA

Grifols, S.A. (GRFS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Bioscience, accounting for 88.2% of total sales, equivalent to $1.92B. Other significant revenue streams include Diagnostics and Others/Raw Materials. Understanding this composition is critical for investors evaluating how GRFS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Grifols, S.A. maintains a gross margin of 37.57%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.56%, while the net margin is 9.77%. These profitability ratios, combined with a Return on Equity (ROE) of 8.43%, provide a clear picture of how effectively GRFS converts its operational activities into shareholder value.

In the context of the broader market, GRFS competes directly with industry leaders such as PTCT and ORKA. With a market capitalization of $5.23B, it holds a significant position in the sector. When comparing efficiency, GRFS's gross margin of 37.57% stands against PTCT's 91.19% and ORKA's N/A. Such benchmarking helps identify whether Grifols, S.A. is trading at a premium or discount relative to its financial performance.

Grifols reported a profit increase of 28.7% in H1 2026, with revenue growth of 2.6% at constant currency, reaching €3.57 billion, primarily driven by its Biopharma segment.